May 13, 2026

Combination Therapy May Increase Lesion Closure in PCV

The combination of photodynamic therapy and intravitreal  aflibercept did not improve 1-year visual acuity outcomes compared with aflibercept monotherapy.

Conexiant

May 05, 2026

Lutein Supplementation May Improve Outcomes in Early AMD

Meta-analysis found statistically significant improvements, with clearest benefits in early-stage disease

Conexiant

May 01, 2026

Racing Toward Efficient AI Workflows

At the Focus A-Eye Summit, in the session “Lessons from Formula One: Optimizing Clinical Workflow with AI,” experts examined how artificial intelligence can streamline and accelerate ophthalmic clinical workflows.

Retinal Physician

April 29, 2026

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

April 28, 2026

Inside the Aging Eye

A comprehensive new Elsevier publication brings global expertise together to unpack how aging drives ocular structure, function, and disease

The Ophthalmologist

April 28, 2026

Inside the Aging Eye

A comprehensive new Elsevier publication brings global expertise together to unpack how aging drives ocular structure, function, and disease

The Ophthalmologist

April 20, 2026

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.

Conexiant

March 31, 2026

Equal Pay in Ophthalmology? Not Yet

A decade of AAMC salary data reveals a persistent gender pay gap in academic ophthalmology—and projects it will never close at senior ranks

Conexiant

March 24, 2026

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

Conexiant

March 24, 2026

Artificial Tears Reduce Dryness Symptoms in 1-Month Study

Prospective multicenter study without a control group shows symptom scores reduced by more than half after 4 weeks of treatment

Conexiant